SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

6990

CNE1000062J1

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 01:38:13 11/02/2026 pm IST			5-day change	1st Jan Change
438.00 ^HKD	+0.18%		+3.60%	+11.68%

06/02	Sichuan Kelun-Biotech biopharmaceutical says Trop2 adc sacituzumab tirumotecan approved for marketing for fourth indication by China's NMPA	RE
06/02	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Fourth Indication for Sacituzumab Tirumotecan (Sac-TMT) Approved by NMPA in HR+/HER2- Breast Cancer	CI

Sichuan Kelun-Biotech Biopharmaceutical says subscription for BOC structured deposit II terminated

Published on 01/07/2026 at 08:46 pm IST

Reuters

Latest news about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

06/02	Sichuan Kelun-Biotech biopharmaceutical says Trop2 adc sacituzumab tirumotecan approved for marketing for fourth indication by China's NMPA	RE
06/02	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Fourth Indication for Sacituzumab Tirumotecan (Sac-TMT) Approved by NMPA in HR+/HER2- Breast Cancer	CI
06/02	Sichuan Kelun-Biotech Secures China Approval for New Breast Cancer Drug Indication	MT
19/01	Sichuan Kelun-Biotech Renews R&D Procurement Deal With China Resources Kelun; Shares Slip 5%	MT
07/01	Sichuan Kelun-Biotech Biopharmaceutical says subscription for BOC structured deposit II terminated	RE
07/01	Sichuan Kelun-Biotech Subscribes to Wealth Management Products	MT
06/01	Sichuan Kelun-Biotech Biopharmaceutical subscribes for wealth management products	RE
05/01	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Breakthrough Therapy Designation for First-Line Treatment of PD-L1 Positive NSCLC by the National Medical Products Administration	CI
05/01	Sichuan Kelun-Biotech Receives Chinese Regulatory Nod to Begin Human Trials of SKB105	MT
05/01	Sichuan Kelun-Biotech Biopharmaceutical SAC-TMT in combination with immunotherapy pembrolizumab granted breakthrough therapy designation by NMPA	RE
05/01	Sichuan Kelun-Biotech Lung Cancer Treatment Granted Breakthrough Therapy Designation in China	MT
04/01	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Investigational New Drug Application for Skb105	CI
31/12	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Sales and Distribution Framework Agreement	CI
20/12	US FDA grants priority vouchers to Merck's cholesterol pill, cancer therapy	RE
16/12	Sichuan Kelun-Biotech biopharmaceutical enters settlement agreement with MediLink Therapeutics (Suzhou), others	RE
05/12	Sichuan Kelun-Biotech Signs Oncology Partnership with Crescent Biopharma; Shares Rise 3%	MT
05/12	China's Kelun-Biotech licenses cancer treatment to Crescent Biopharma	RE
04/12	Sichuan Kelun-Biotech biopharmaceutical partners with Crescent Biopharma	RE
04/12	Kelun-Biotech and Crescent Biopharma announce strategic partnership	RE
04/12	Crescent Biopharma, Inc. Announces Transformational Partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd	CI
04/12	Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics	CI
28/11	The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Cararcinoma	CI
24/11	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA®? (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint	CI
10/11	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Presented TROP2 ADC Sacituzumab Tirumotecan Results from Multiple Clinical Studies at the 2025 Chinese Congress	CI
20/25/20	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO	CI

Chart Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Duration

Period

Chart Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

6990: Dynamic Chart

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a China-based company mainly engages in the research and development, production and sales of drugs. The Company is mainly engaged in the research and development, manufacturing and commercialization of innovative drugs in oncology, immunology and other therapeutic fields. The Company's products are antibody-drug conjugates (ADCs) SKB264 and A166. The Company's products are mainly used for the treatment of breast cancer, non-small cell lung cancer, Gastrointestinal cancer and other non tumor diseases.

Employees

1,870

Sector

Biotechnology & Medical Research

Calendar

30/03 - Q4 2025 Earnings Release (Projected)

More about the company